Becton, Dickinson & Co. is investing more than $30 million to boost its U.S. manufacturing of intravenous catheters.
The additional production lines at its plant in Sandy, Utah, follows previous investments of more than $12 million in its U.S. manufacturing network to increase its supply of syringes, needles and intravenous catheters.
Related: Trump's tariff threat troubles medtech industry
Supply chain issues are top of mind at medtech companies, which may be looking to strengthen their domestic manufacturing if President-elect Donald Trump makes good on his plans to impose tariffs on goods from Canada, Mexico and China. Philips CEO Roy Jakobs, during the J.P. Morgan Healthcare Conference, called the tariffs "price enhancing" and said the company is working on its productivity expansion.
Eric Borin, president of medication delivery solutions at Becton Dickinson, said in a news release that domestic manufacturing is "crucial for ensuring a resilient supply of essential healthcare devices."
The new lines will produce hundreds of millions of new products annually, increasing the company’s production of safety-engineered injection devices by more than 40% and conventional syringes by over 50%.
Becton, Dickinson operates more 30 manufacturing and distribution facilities in the U.S., which employ 10,000-plus people.